Head-to-Head Trial of Paclitaxel Formulations Shows Advantage for Nanoparticle Agent

Oncology Times
February 10, 2015
Head-to-Head Trial of Paclitaxel Formulations Shows Advantage for Nanoparticle Agent

Dr. Daniel Budman, Associate Chief, Medical Oncology & Hematology, North Shore-LIJ Cancer Institute

Read this Story

Focus onHealth TV

Watch Focus onHealth, Northwell Health's TV show. It's the healthy way to stay informed!